Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention
Matteo Foschi, Senior Consultant Neurologist at Romagna Local Health Authority (AUSL Romagna), Fellow of the European Stroke Organisation (FESO), Guidelines Production Board at European Stroke Organisation, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Stroke, adding:
“New commentary out in Stroke!
I am very happy to share our new contribution to InterSECT — The International Stroke Early Career and Training Section.
In ‘Antithrombotic Therapy in Secondary Stroke Prevention: 10 Clinical Pearls Every Clinician Should Know‘, we tried to distill an increasingly complex evidence base into 10 practical take-home messages for everyday clinical decision-making:
- Know your enemy – match antithrombotic therapy to the stroke mechanism.
- Know your antiplatelet arsenal – tailor intensity and DAPT duration to ischemic risk.
- Stroke on antiplatelets? Don’t just switch – first reassess adherence, interactions and competing mechanisms.
- When the heart is the culprit, anticoagulation is the answer.
- Timing matters – after AF-related stroke, think imaging rather than rigid timelines.
- Stroke despite anticoagulation? Re-think before changing – look for underdosing, non-adherence, interactions and competing etiologies.
- After intracranial bleeding, restarting anticoagulation is a decision – not a reflex.
- One size does not fit all – renal function, frailty, neuroimaging, genetics and comorbidities matter.
- Prevention is a marathon – treatment needs continuous reassessment over time.
- No access, no effect – even the best treatment cannot work without access, adherence and continuity of care.
A special thanks to InterSECT Section Editor Ahmed Nasreldein for inviting us to develop this proposal.
A pleasure to work on this with Lucio D’Anna, Federico De Santis, Raffaele Ornello, and Simona Sacco.”
Title: Antithrombotic Therapy in Secondary Stroke Prevention: 10 Clinical Pearls Every Clinician Should Know
Authors: Matteo Foschi, Lucio D’Anna, Federico De Santis, Raffaele Ornello, Simona Sacco

Other posts featuring Matteo Foschi on Hemostasis Today.
-
Nov 15, 2026, 10:32Ibrahim Gwarzo: Identifying Care Gaps and Emergency Pain Delays in Sickle Cell Disease at APHA 2026
-
Nov 15, 2026, 10:17Ify Osunkwo: How the Sickle Cell Community Can Influence FDA Drug Development Priorities
-
Nov 15, 2026, 10:11Ahmed Abdelsalam: Why Matching ABO and RhD Groups Does Not Guarantee Crossmatch Compatibility
-
Nov 15, 2026, 10:06Asma Khalil: New British Society for Haematology Guidance on Paediatric and Neonatal Transfusion
-
Nov 15, 2026, 09:41Girishkumar Modi: Navigating the 2026 Jehovah’s Witness Transfusion Policy Shift in Clinical Practice
-
Nov 15, 2026, 04:31Aakriti Gupta: Anticoagulation for Leaflet Thickening After TAVR
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis